Morphine-nicotine interaction in conditioned place preference in mice after chronic nicotine exposure

European Journal of Pharmacology

Volumn 587, Issue 1-3, 2008, Pages 169-174

  Vihavainen, Tanja ^a   Piltonen, Marjo ^a   Tuominen, Raimo K ^a   Korpi, Esa R ^b   Ahtee, Liisa ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

35S GTP S; 3H DAMGO; Conditioned place preference; Cross sensitization; Morphine; Nicotine

Indexed keywords

ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MORPHINE; MU OPIATE RECEPTOR; NICOTINE; SULFUR 35; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT;

ANALGESICS, OPIOID; ANIMALS; AUTORADIOGRAPHY; CONDITIONING, OPERANT; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; MICE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, OPIOID, MU;

EID: 44349159464     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.03.028     Document Type: Article

References (61)

1. Berrendero F., Kieffer B.L., and Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice. J. Neurosci. 22 (2002) 10935-10940
2. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., and Maldonado R. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J. Neurosci. 25 (2005) 1103-1112
3. Biala G., and Weglinska B. Calcium channel antagonists attenuate cross-sensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J. Pharm. Pharmacol. 56 (2004) 1021-1028
4. Blander A., Hunt T., Blair R., and Amit Z. Conditioned place preference: an evaluation of morphine's positive reinforcing properties. Psychopharmacology (Berl) 84 (1984) 124-127
5. Davenport K.E., Houdi A.A., and Van Loon G.R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113 (1990) 40-46
6. Dhatt R.K., Gudehithlu K.P., Wemlinger T.A., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J. Neurochem. 64 (1995) 1878-1883
7. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 5274-5278
8. Fiserova M., Consolo S., and Krsiak M. Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: an in vivo microdialysis study. Psychopharmacology (Berl) 142 (1999) 85-94
9. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, Inc., San Diego (CA), USA
10. Fudala P.J., Teoh K.W., and Iwamoto E.T. Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol. Biochem. Behav. 22 (1985) 237-241
11. Gäddnäs H., Pietilä K., and Ahtee L. Effects of chronic oral nicotine treatment and its withdrawal on locomotor activity and brain monoamines in mice. Behav. Brain Res. 113 (2000) 65-72
12. Galeote L., Kieffer B.L., Maldonado R., and Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. J. Neurochem. 97 (2006) 416-423
13. Gentry C.L., and Lukas R.J. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 359-385
14. Gerdeman G.L., Partridge J.G., Lupica C.R., and Lovinger D.M. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci. 26 (2003) 184-192
15. Glick S.D., Kuehne M.E., Maisonneuve I.M., Bandarage U.K., and Molinari H.H. 18-methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res. 719 (1996) 29-35
16. Grenhoff J., Aston-Jones G., and Svensson T.H. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 128 (1986) 351-358
17. Hiramatsu M., Murasawa H., Nabeshima T., and Kameyama T. Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats. J. Pharmacol. Exp. Ther. 284 (1998) 858-867
18. Houdi A.A., Dasgupta R., and Kindy M.S. Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA. Brain Res. 799 (1998) 257-263
19. Hyytiä P., Ingman K., Soini S.L., Laitinen J.T., and Korpi E.R. Effects of continuous opioid receptor blockade on alcohol intake and up-regulation of opioid receptor subtype signalling in a genetic model of high alcohol drinking. Naunyn Schmiedebergs Arch. Pharmacol. 360 (1999) 391-401
20. Isola R., Zhang H., Duchemin A.M., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse. Neurosci. Lett. 325 (2002) 67-71
21. Jackson K.J., Martin B.R., Changeux J.P., and Damaj M.I. Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J. Pharmacol. Exp. Ther. 325 (2008) 302-312
22. Johnson S.W., and North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12 (1992) 483-488
23. Koob G.F. Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur. Neuropsychopharmacol. 13 (2003) 442-452
24. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
25. Koob G.F., and Le Moal M. Neurobiology of Addiction (2006), Elsevier Academic Press, San Diego, CA
26. 35S]thio)triphosphate autoradiography allows selective detection of histamine H3 receptor-dependent G protein activation in rat brain tissue sections. J. Neurochem. 71 (1998) 808-816
27. Lesscher H.M., Bailey A., Burbach J.P., Van Ree J.M., Kitchen I., and Gerrits M.A. Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice. Eur. J. Neurosci. 17 (2003) 1006-1012
28. Marco E.M., Granstrem O., Moreno E., Llorente R., Adriani W., Laviola G., and Viveros M.P. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur. J. Pharmacol. 557 (2007) 37-43
29. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., and Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383 (1996) 819-823
30. Mucha R.F., and Iversen S.D. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology (Berl) 82 (1984) 241-247
31. Mucha R.F., and Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl) 86 (1985) 274-280
32. Mucha R.F., van der Kooy D., O'Shaughnessy M., and Bucenieks P. Drug reinforcement studied by the use of place conditioning in rat. Brain Res. 243 (1982) 91-105
33. Nowycky M.C., Walters J.R., and Roth R.H. Dopaminergic neurons: effect of acute and chronic morphine administration on single cell activity and transmitter metabolism. J. Neural Transm. 42 (1978) 99-116
34. Nuutinen S., Ahtee L., and Tuominen R.K. Time and brain region specific up-regulation of low affinity neuronal nicotinic receptors during chronic nicotine administration in mice. Eur. J. Pharmacol. 515 (2005) 83-89
35. Osman N.I., Baghdoyan H.A., and Lydic R. Morphine inhibits acetylcholine release in rat prefrontal cortex when delivered systemically or by microdialysis to basal forebrain. Anesthesiology 103 (2005) 779-787
36. Pekonen K., Karlsson C., Laakso I., and Ahtee L. Plasma nicotine and cotinine concentrations after chronic oral nicotine administration and challenge doses. Eur. J. Pharm. Sci. 1 (1993) 13-18
37. Phillips A.G., and LePiane F.G. Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacol. Biochem. Behav. 12 (1980) 965-968
38. Piepponen T.P., Kivastik T., Katajamaki J., Zharkovsky A., and Ahtee L. Involvement of opioid mu 1 receptors in morphine-induced conditioned place preference in rats. Pharmacol. Biochem. Behav. 58 (1997) 275-279
39. Piepponen T.P., Honkanen A., Kivastik T., Zharkovsky A., Turtia A., Mikkola J.A., and Ahtee L. Involvement of opioid μ1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission. Pharmacol. Biochem. Behav. 63 (1999) 245-252
40. Pietilä, K., 1998. Central nervous system effects of chronic nicotine administration in mice. Dissertationes Biocentri Viikki Universitatis Helsingiensis.
41. Pietilä K., Lähde T., Attila M., Ahtee L., and Nordberg A. Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn Schmiedebergs Arch. Pharmacol. 357 (1998) 176-182
42. Rezayof A., Zatali H., Haeri-Rohani A., and Zarrindast M.R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward. Behav. Brain Res. 166 (2006) 281-290
43. Rezayof A., Nazari-Serenjeh F., Zarrindast M.R., Sepehri H., and Delphi L. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area. Eur. J. Pharmacol. 562 (2007) 92-102
44. Shippenberg T.S., Bals-Kubik R., and Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J. Pharmacol. Exp. Ther. 265 (1993) 53-59
45. Shippenberg T.S., Heidbreder C., and Lefevour A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. Eur. J. Pharmacol. 299 (1996) 33-39
46. Soini S.L., Hyytiä P., and Korpi E.R. Brain regional mu-opioid receptor function in rat lines selected for differences in alcohol preference. Eur. J. Pharmacol. 448 (2002) 157-163
47. Spanagel R., Herz A., and Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55 (1990) 1734-1740
48. Spiga R., Schmitz J., and Day II J. Effects of nicotine on methadone self-administration in humans. Drug Alcohol Depend. 50 (1998) 157-165
49. Spyraki C., Fibiger H.C., and Phillips A.G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology (Berl) 79 (1983) 278-283
50. Sutherland R.J. The dorsal diencephalic conduction system: a review of the anatomy and functions of the habenular complex. Neurosci. Biobehav. Rev. 6 (1982) 1-13
51. Taguchi K., Hagiwara Y., Suzuki Y., and Kubo T. Effects of morphine on release of acetylcholine in the rat striatum: an in vivo microdialysis study. Naunyn Schmiedebergs Arch. Pharmacol. 347 (1993) 9-13
52. Taraschenko O.D., Rubbinaccio H.Y., Shulan J.M., Glick S.D., and Maisonneuve I.M. Morphine-induced changes in acetylcholine release in the interpeduncular nucleus and relationship to changes in motor behavior in rats. Neuropharmacology 53 (2007) 18-26
53. Taraschenko O.D., Shulan J.M., Maisonneuve I.M., and Glick S.D. 18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens. Synapse 61 (2007) 547-560
54. Taylor R.C., Harris N.A., Singleton E.G., Moolchan E.T., and Heishman S.J. Tobacco craving: intensity-related effects of imagery scripts in drug abusers. Exp. Clin. Psychopharmacol. 8 (2000) 75-87
55. Vihavainen T., Mijatovic J., Piepponen T.P., Tuominen R.K., and Ahtee L. Effect of morphine on locomotor activity and striatal monoamine metabolism in nicotine-withdrawn mice. Behav. Brain Res. 173 (2006) 85-93
56. Walters C.L., Cleck J.N., Kuo Y.C., and Blendy J.A. μ-Opioid receptor and CREB activation are required for nicotine reward. Neuron 46 (2005) 933-943
57. Wewers M.E., Dhatt R.K., Snively T.A., and Tejwani G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res. 822 (1999) 107-113
58. Wise R.A. Forebrain substrates of reward and motivation. J. Comp. Neurol. 493 (2005) 115-121
59. Zachariou V., Caldarone B.J., Weathers-Lowin A., George T.P., Elsworth J.D., Roth R.H., Changeux J.P., and Picciotto M.R. Nicotine receptor inactivation decreases sensitivity to cocaine. Neuropsychopharmacology 24 (2001) 576-589
60. Zarrindast M.R., Faraji N., Rostami P., Sahraei H., and Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol. Biochem. Behav. 74 (2003) 363-369
61. Zarrindast M.R., Fattahi Z., Rostami P., and Rezayof A. Role of the cholinergic system in the rat basolateral amygdala on morphine-induced conditioned place preference. Pharmacol. Biochem. Behav. 82 (2005) 1-10